Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
60.74B
Market cap60.74B
Price-Earnings ratio
1.92K
Price-Earnings ratio1.92K
Dividend yield
Dividend yield
Average volume
855.44K
Average volume855.44K
High today
$463.49
High today$463.49
Low today
$456.90
Low today$456.90
Open price
$462.27
Open price$462.27
Volume
289.86K
Volume289.86K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $459.79. The company's market cap stands at 60.74B, with a P/E ratio of 1923.04.

As of 2025-11-19, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $456.90 and $463.49. The current price stands at $459.79, placing the stock +0.6% above today's low and -0.8% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 289.86K, compared to an average daily volume of 855.44K.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

ALNY News

Nasdaq 2d
Validea Detailed Fundamental Analysis - ALNY

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Mome...

Validea Detailed Fundamental Analysis - ALNY
Simply Wall St 5d
Is Amyloid Regression and Kidney Preservation Data From HELIOS-B Shifting the Investment Case for Alnylam?

Earlier this week, Alnylam Pharmaceuticals announced and presented new post hoc analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), revealing am...

Is Amyloid Regression and Kidney Preservation Data From HELIOS-B Shifting the Investment Case for Alnylam?

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
26.7%
Sell
3.3%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.